Key Takeaways
- As of December 29, Health Canada has received nine submissions from drug companies seeking approval to make generic versions of the blockbuster drug Ozempic.
- Experts say that patients should not expect the generic version to be available for at least a few months, with a likely release date in late spring or early summer.
- The generic version of Ozempic is expected to be priced as low as 35% of the brand-name cost, which could make it more affordable for patients with Type 2 diabetes and obesity.
- The introduction of generic semaglutide is expected to increase competition and drive down prices, making the medication more accessible to patients who cannot afford the brand-name version.
Introduction to Generic Ozempic
The Canadian pharmaceutical market is on the verge of a significant change with the introduction of generic versions of the blockbuster drug Ozempic. As of December 29, Health Canada had received nine submissions from drug companies seeking approval to make semaglutide, the active ingredient in Ozempic and Wegovy, the brand-name diabetes and weight-loss drugs manufactured by Novo Nordisk. This development is expected to increase competition and drive down prices, making the medication more accessible to patients who cannot afford the brand-name version.
The Approval Process
The approval process for generic semaglutide is complex and time-consuming. Health Canada’s spokesperson, Mark Johnson, stated that the "target timeline" for the scientific review of generic drug submissions is 180 days, but this does not include the extra time required if Health Canada needs more information from the drug company. Evaluating generic semaglutide drugs is more complex than many other medication approvals because semaglutide was originally developed using biological processes, but the generic versions can be made using more simple chemical means. Johnson noted that "generic semaglutide products are complex synthetic products that are pharmaceutically equivalent to the brand name drug, but with possible differences that could impact safety and efficacy."
Expected Timelines and Pricing
Mina Tadrous, a pharmaceutical policy expert at the University of Toronto, said that a generic semaglutide medication is unlikely to be approved until late spring or early summer. Patients can expect the drug to be priced as low as 35% of the brand-name Ozempic cost, which can be a few hundred dollars a month. Tadrous noted that there will likely be multiple generic semaglutide medications competing with each other, which will drive down prices and make the medication more affordable for patients.
Impact on Patients and Healthcare
The introduction of generic semaglutide is expected to have a significant impact on patients with Type 2 diabetes and obesity. Dr. Ehud Ur, an endocrinologist in Vancouver, said that being able to prescribe generic semaglutide will be "very exciting" and that the medication would be an effective treatment for many of his patients, but they are not on it because they cannot afford it. Ur noted that the price of Ozempic is a significant barrier for many patients, with costs ranging from $200 to $400 per month. The introduction of generic semaglutide is expected to make the medication more affordable and increase access to treatment for patients who need it.
Competition and Market Dynamics
The introduction of generic semaglutide is also expected to change the market dynamics of the pharmaceutical industry. Novo Nordisk’s main competitor, Eli Lilly, still holds its patent in Canada for its drugs Mounjaro and Zepbound, which contain the active ingredient tirzepatide. Eli Lilly remains confident in the differentiated benefits of tirzepatide, but it is unclear whether the company will provide cost savings to patients in order to compete with generic semaglutide. The introduction of generic semaglutide is expected to increase competition and drive down prices, making the medication more accessible to patients who cannot afford the brand-name version.
Conclusion
The introduction of generic Ozempic is a significant development in the Canadian pharmaceutical market. With multiple drug companies seeking approval to make generic versions of the medication, patients can expect increased competition and lower prices. While the approval process is complex and time-consuming, experts expect that the generic version will be available in late spring or early summer. The introduction of generic semaglutide is expected to make the medication more affordable and increase access to treatment for patients with Type 2 diabetes and obesity. As the market dynamics continue to evolve, it will be important to monitor the impact of generic semaglutide on patients and the pharmaceutical industry as a whole.